PATENT CLAIM ANALYSIS

Application Number: 15989532
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["424", "136100"]

Abstract:
Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.

Claim (Index 16):
The method of  claim 11 , wherein the cancer is an epithelial cell cancer, breast cancer, ovarian cancer, lung cancer, non-small cell lung cancer (NSCLC), lung adenocarcinoma, small cell lung cancer, colorectal cancer, anal cancer, prostate cancer, kidney cancer, bladder cancer, head and neck cancer, pharynx cancer, cancer of the nose, pancreatic cancer, skin cancer, oral cancer, cancer of the tongue, esophageal cancer, vaginal cancer, cervical cancer, cancer of the spleen, testicular cancer, gastric cancer, cancer of the thymus, colon cancer, thyroid cancer, liver cancer, hepatocellular carcinoma (HCC) or sporadic or hereditary papillary renal cell carcinoma (PRCC).

Metadata:
- Claim Count in Document: 20.0
- Percentile: 93.0
- Lexical Diversity: 1.09091
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14283257', '15386195', '14086588', '14086250', '14085340']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8624037277713404
- 35 USC 102 Novelty (BERT): 0.6952300878060093
- Combined Prediction Score: 0.8456863637748073
- Mean Citation Score: 723.874022
- Max Citation Score: 927.17365
- Similarity Product: 703.7303850942372

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test